Skip to content
lifestyle.paraskevas.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tris Pharma, Inc.
Tris Pharma Announces FDA Grant of Orphan Drug Designation for TRN-257 (Oxybate for Extended-Release Oral Suspension) a Once-Nightly, Low-Sodium Oxybate Product for Idiopathic Hypersomnia
June 10, 2026
Tris Pharma Announces Presentation on The Complexity and Management of ADHD at Psych Congress Elevate 2026
June 2, 2026
Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer
May 5, 2026
Tris Pharma to Showcase Encore Phase 3 Data Supporting Continued Progress in Acute Pain Treatment at ASRA 2026 Meeting in Phoenix
April 8, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
March 6, 2026